Mandate

Vinge has advised Magle Chemoswed Holding AB in connection with its listing on Nasdaq First North Growth Market

Vinge has provided capital markets and transaction advice in connection with Magle Chemoswed Holding AB’s listing on Nasdaq First North Growth Market.

The prospectus was published on 2 June 2020 and trading on Nasdaq First North Growth Market was commenced on 30 June 2020. The offer related to 25 per cent of the total number of existing shares and following full subscription the value of the offer amounted to SEK 50 million.

Magle Chemoswed is an international contract development and manufacturing company and also develops its own product portfolio based on the company’s technology platforms. The company owns its manufacturing and development facilities in Malmö and works in relation to the development and manufacture of pharmaceuticals and medical devices on a contract basis. On 31 March 2020, the company had 70 employees and in 2019, the net turnover amounted to approximately SEK 128 million.

Vinge’s team consisted primarily of Kristian Ford, Christian Lindhé, Martin Svanberg, Sophia Reutercrona, Niklas Törnell, Tilda Hall, Daniel Melander Björner and Johan Cederblad.

Related

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025